Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Other material event · Financial statements
Transcode Therapeutics, Inc.
10
Other material event
Jun 3, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Other material event · Financial statements |
| Primary topic | Other material event |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | Transcode Therapeutics, Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics. BOSTON, June 3,… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 3, 2026 |
| Accession number | 0001104659-26-069810 |
| Reported items | Other events the company considers material, Financial statements and exhibits See Analysis tab for workforce implications |
